Medullary Thyroid Cancer Clinical Trial
Official title:
Predective Factors for Tumor Aggressiveness in Medullary Thyroid Cancer
This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.
This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival. The predictive factors included in this study are central and lateral compartment lymph node metastases as well as distant metastasis up to 1 year postoperatively, while biochemical predictors (meaning ratios such as lymphocyte to monocyte ratio etc and CEA and calcitonin drop levels) and histological predictors (such as nuclear atypia, amyloid, immunohistochemistry, desmoplasia) are included as secondary outcomes. In this study , patients >18 years old that underwent surgery for medullary thyroid cancer (total thyroidectomy, completion thyroidectomy) +/- central/lateral neck dissection) will be enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03643055 -
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
|
||
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06277180 -
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
|
N/A | |
| Withdrawn |
NCT04760288 -
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
|
Phase 3 | |
| Not yet recruiting |
NCT06079723 -
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
|
||
| Recruiting |
NCT01739634 -
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03157128 -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
|
Phase 1/Phase 2 | |
| Completed |
NCT02856347 -
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
|
N/A | |
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04280081 -
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
|
Phase 2 | |
| Completed |
NCT01757470 -
Vandetanib Risk Minimisation Effectiveness
|
N/A | |
| Recruiting |
NCT05830500 -
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
|
Phase 4 | |
| Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01660984 -
Natural History Study of Children and Adults With Medullary Thyroid Cancer
|
||
| Withdrawn |
NCT03838692 -
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
|
Phase 2 | |
| Terminated |
NCT02363647 -
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
|
N/A | |
| Terminated |
NCT00582712 -
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT06141369 -
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
|
N/A | |
| Completed |
NCT06243965 -
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
|
||
| Active, not recruiting |
NCT01298323 -
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
|
Phase 3 |